HRP20220234T1 - Kristalni oblici - Google Patents

Kristalni oblici Download PDF

Info

Publication number
HRP20220234T1
HRP20220234T1 HRP20220234TT HRP20220234T HRP20220234T1 HR P20220234 T1 HRP20220234 T1 HR P20220234T1 HR P20220234T T HRP20220234T T HR P20220234TT HR P20220234 T HRP20220234 T HR P20220234T HR P20220234 T1 HRP20220234 T1 HR P20220234T1
Authority
HR
Croatia
Prior art keywords
4carbonyl
phosphono
pyrrolidin
propionyl
piperazine
Prior art date
Application number
HRP20220234TT
Other languages
English (en)
Croatian (hr)
Inventor
Daniel Leuenberger
Stefan Reber
Markus Von Raumer
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of HRP20220234T1 publication Critical patent/HRP20220234T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20220234TT 2016-09-22 2017-09-21 Kristalni oblici HRP20220234T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22
PCT/EP2017/073858 WO2018055016A1 (en) 2016-09-22 2017-09-21 Crystalline forms
EP17771436.7A EP3515924B1 (en) 2016-09-22 2017-09-21 Crystalline forms

Publications (1)

Publication Number Publication Date
HRP20220234T1 true HRP20220234T1 (hr) 2022-05-13

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220234TT HRP20220234T1 (hr) 2016-09-22 2017-09-21 Kristalni oblici

Country Status (27)

Country Link
US (4) US10730896B2 (enExample)
EP (2) EP3515924B1 (enExample)
JP (1) JP7097369B2 (enExample)
KR (1) KR102552795B1 (enExample)
CN (1) CN109715639B (enExample)
AU (1) AU2017331930B2 (enExample)
CA (1) CA3037794A1 (enExample)
CL (1) CL2019000728A1 (enExample)
CY (1) CY1125052T1 (enExample)
DK (1) DK3515924T3 (enExample)
EA (1) EA201990723A1 (enExample)
ES (1) ES2908572T3 (enExample)
HR (1) HRP20220234T1 (enExample)
HU (1) HUE057772T2 (enExample)
IL (1) IL265445B2 (enExample)
LT (1) LT3515924T (enExample)
MA (1) MA46266B1 (enExample)
MX (1) MX381590B (enExample)
MY (1) MY193080A (enExample)
PH (1) PH12019500567B1 (enExample)
PL (1) PL3515924T3 (enExample)
PT (1) PT3515924T (enExample)
RS (1) RS62946B1 (enExample)
SI (1) SI3515924T1 (enExample)
TW (1) TWI752086B (enExample)
UA (1) UA124073C2 (enExample)
WO (1) WO2018055016A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3515924T3 (da) 2016-09-22 2022-03-21 Idorsia Pharmaceuticals Ltd Krystallinske former
SG11201908128YA (en) 2017-03-15 2019-10-30 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a p2y12 receptor antagonist
RS67649B1 (sr) 2020-07-15 2026-02-27 Viatris Asia Pacific Pte Ltd Vodena farmaceutska kompozicija koja sadrži antagonistu p2y12 receptora
IL309948A (en) * 2021-07-13 2024-03-01 Idorsia Pharmaceuticals Ltd A process for the synthesis of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidin-4-carbonyl]-amino}-3-phosphono- Propionyl)-piperazine-1-carboxylic acid butyl ester

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
ES2248084T3 (es) 1999-06-14 2006-03-16 Eli Lilly And Company Inhibidores de serinproteasa.
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
EA200500899A1 (ru) 2002-12-11 2006-02-24 Шеринг Акциенгезельшафт Антагонисты аденозиндифосфатного рецептора тромбоцитов
US7253153B2 (en) 2003-04-09 2007-08-07 Wyeth Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
TWI382976B (zh) 2005-10-21 2013-01-21 Actelion Pharmaceuticals Ltd 作為抗瘧疾劑之新穎哌
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
WO2008128647A1 (en) 2007-04-23 2008-10-30 Sanofi-Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
JP4729133B2 (ja) 2007-11-29 2011-07-20 アクテリオン ファーマシューティカルズ リミテッド ホスホン酸誘導体及びp2y12受容体拮抗剤としてのそれらの使用
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
WO2009080226A2 (en) 2007-12-26 2009-07-02 Sanofis-Aventis Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
CA2756542C (en) 2009-04-08 2017-08-22 Actelion Pharmaceuticals Ltd 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines
CA2756654C (en) 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
DK3515924T3 (da) 2016-09-22 2022-03-21 Idorsia Pharmaceuticals Ltd Krystallinske former
SG11201908128YA (en) 2017-03-15 2019-10-30 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a p2y12 receptor antagonist
RS67649B1 (sr) 2020-07-15 2026-02-27 Viatris Asia Pacific Pte Ltd Vodena farmaceutska kompozicija koja sadrži antagonistu p2y12 receptora

Also Published As

Publication number Publication date
PH12019500567A1 (en) 2019-11-18
US11365209B2 (en) 2022-06-21
IL265445A (en) 2019-05-30
MA46266A (fr) 2019-07-31
JP7097369B2 (ja) 2022-07-07
BR112019004845A2 (pt) 2019-06-04
MY193080A (en) 2022-09-26
CL2019000728A1 (es) 2019-07-05
EP3515924B1 (en) 2021-12-15
JP2019529553A (ja) 2019-10-17
US20200017534A1 (en) 2020-01-16
KR102552795B1 (ko) 2023-07-06
PH12019500567B1 (en) 2024-01-31
US12227532B2 (en) 2025-02-18
TW201813965A (zh) 2018-04-16
US20210009614A1 (en) 2021-01-14
AU2017331930A1 (en) 2019-03-07
MA46266B1 (fr) 2022-02-28
IL265445B1 (en) 2024-01-01
LT3515924T (lt) 2022-03-10
ES2908572T3 (es) 2022-05-03
KR20190052704A (ko) 2019-05-16
MX2019003093A (es) 2019-07-18
EP3981774A1 (en) 2022-04-13
DK3515924T3 (da) 2022-03-21
IL265445B2 (en) 2024-05-01
EA201990723A1 (ru) 2019-10-31
CA3037794A1 (en) 2018-03-29
US20220275011A1 (en) 2022-09-01
AU2017331930B2 (en) 2021-07-15
CN109715639B (zh) 2022-04-19
TWI752086B (zh) 2022-01-11
US20250163086A1 (en) 2025-05-22
EP3515924A1 (en) 2019-07-31
CN109715639A (zh) 2019-05-03
CY1125052T1 (el) 2024-02-16
US10730896B2 (en) 2020-08-04
PL3515924T3 (pl) 2022-04-11
RS62946B1 (sr) 2022-03-31
WO2018055016A1 (en) 2018-03-29
MX381590B (es) 2025-03-12
SI3515924T1 (sl) 2022-04-29
PT3515924T (pt) 2022-03-11
UA124073C2 (uk) 2021-07-14
HUE057772T2 (hu) 2022-06-28
NZ750772A (en) 2023-10-27

Similar Documents

Publication Publication Date Title
AR128483A2 (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, sus composiciones y usos
HRP20220234T1 (hr) Kristalni oblici
HRP20160813T1 (hr) Natrijeve i kalcijeve soli derivata dihidrokinazolina i njihova upotreba kao antivirusna sredstva
HRP20210675T1 (hr) Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa
BRPI0407149A8 (pt) formas polimórficas de rifaximin, processos para sua produção e seu uso em preparações medicinais
JP2018520205A5 (enExample)
HRP20201343T1 (hr) Kristalni oblici 5-kloro-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoksi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidin-2,4-diamina
FI4293009T3 (fi) Fenfluramiinikoostumukset ja menetelmät niiden valmistamiseksi
HRP20241280T1 (hr) Kruti oblici rukapariba i soli rukapariba
HRP20160886T1 (hr) Besilatna i tosilatna sol derivata dihidrokinazolina i njihova upotreba kao protuvirusna sredstva
EA201990688A1 (ru) Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение
EP4327880A3 (en) Solid state form of ribociclib succinate
HRP20210551T1 (hr) Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za liječenje shizofrenije
EA200901146A1 (ru) Твердые лекарственные формы, содержащие алискирен и его фармацевтически приемлемые соли
WO2015011120A3 (en) Salts of dasatinib in crystalline form
HRP20201470T1 (hr) Oblici soli nilotiniba u krutom stanju
JP2019529553A5 (enExample)
HRP20250660T1 (hr) Čvrsti oblici ixazomib citrata
JP2016539112A5 (enExample)
JP2018502165A5 (enExample)
CN103819379A (zh) 维生素d3的胆甾烷醇共结晶及其制备方法和应用
HRP20211524T1 (hr) Sol derivata cefalosporina, kristalni kruti oblik istog i postupak za njegovu proizvodnju
MX358669B (es) Croman-6-iloxi-cicloalcanos sustituidos y su uso como productos farmaceuticos.
RU2017131286A (ru) Новые полиморфные формы миноциклинового основания и способы их получения
HRP20251324T1 (hr) Oblici soli rukapariba u krutom stanju